Breast cancer stromal myxoid changes are associated with tumor invasion and metastasis: a central role for hyaluronan
- PMID: 12591961
- DOI: 10.1097/01.MP.0000051582.75890.2D
Breast cancer stromal myxoid changes are associated with tumor invasion and metastasis: a central role for hyaluronan
Abstract
The interplay between a tumor and its environment is exemplified by the morphological changes observed in the stroma of human breast cancer. These changes are evident as stromal myxoid changes. Hyaluronan, an extracellular polysaccharide that has been implicated in invasion, is one of the major constituents of the stromal myxoid changes. This study evaluated the association of these stromal changes with axillary node status, tumor grade, and mortality. The prognostic value of the stromal myxoid changes was evaluated in patients with negative axillary nodes with 10 years of follow-up. Our results showed a high level of reproducibility of our stromal myxoid changes grading system (overall kappa = 0.68). Image analysis semiquantification showed marked correlation of a strong stromal hyaluronan signal with high-grade stromal myxoid changes. In a multiple logistic regression analysis, positive nodes were associated with stromal myxoid changes, tumor size, desmoplasia, lymphocytic infiltration, high tumor grade, tumor emboli, and multifocality. Stromal myxoid changes were also associated with young age and lymphatic embolizations (P <.001). Overall, there is a weak correlation between mortality and stromal myxoid changes (P <.01). Mortality was more evident with high stromal myxoid changes grades and tumor size >2 cm (P <.008). However Cox multivariate analysis fail to show stromal myxoid changes as an independent prognostic factor. In conclusion, stromal myxoid changes with high hyaluronan concentration are strongly associated with positive nodes, tumor grade, and lymphatic emboli, thereby identifying high-risk group and reinforcing the role of hyaluronan in invasion and metastasis.
Similar articles
-
TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.BMC Cancer. 2007 Aug 10;7:156. doi: 10.1186/1471-2407-7-156. BMC Cancer. 2007. PMID: 17692120 Free PMC article.
-
LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.Anticancer Res. 2004 Jul-Aug;24(4):2391-400. Anticancer Res. 2004. PMID: 15330189
-
Versican in nonsmall cell lung cancer: relation to hyaluronan, clinicopathologic factors, and prognosis.Hum Pathol. 2005 Jan;36(1):44-50. doi: 10.1016/j.humpath.2004.10.010. Hum Pathol. 2005. PMID: 15712181
-
[Medullary carcinoma of the breast. What remains of this entity today?].Arch Anat Cytol Pathol. 1995;43(1-2):44-50. Arch Anat Cytol Pathol. 1995. PMID: 7794026 Review. French.
-
Hyaluronan in human malignancies.Exp Cell Res. 2011 Feb 15;317(4):383-91. doi: 10.1016/j.yexcr.2010.11.017. Epub 2010 Dec 3. Exp Cell Res. 2011. PMID: 21134368 Review.
Cited by
-
CD105 expression on CD34-negative spindle-shaped stromal cells of primary tumor is an unfavorable prognostic marker in early breast cancer patients.PLoS One. 2015 Mar 24;10(3):e0121421. doi: 10.1371/journal.pone.0121421. eCollection 2015. PLoS One. 2015. PMID: 25803686 Free PMC article.
-
Hyaluronan and RHAMM in wound repair and the "cancerization" of stromal tissues.Biomed Res Int. 2014;2014:103923. doi: 10.1155/2014/103923. Epub 2014 Aug 4. Biomed Res Int. 2014. PMID: 25157350 Free PMC article. Review.
-
CD105 expression in cancer-associated fibroblasts: a biomarker for bone metastasis in early invasive ductal breast cancer patients.Front Cell Dev Biol. 2023 Aug 31;11:1250869. doi: 10.3389/fcell.2023.1250869. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37719885 Free PMC article.
-
Hyaluronic acid predicts poor prognosis in breast cancer patients: A protocol for systematic review and meta analysis.Medicine (Baltimore). 2020 May 29;99(22):e20438. doi: 10.1097/MD.0000000000020438. Medicine (Baltimore). 2020. PMID: 32481447 Free PMC article.
-
Safety and pharmacokinetics of docetaxel in combination with pegvorhyaluronidase alfa in patients with non-small cell lung cancer.Clin Transl Sci. 2021 Sep;14(5):1875-1885. doi: 10.1111/cts.13041. Epub 2021 Jul 30. Clin Transl Sci. 2021. PMID: 33982408 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical